Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis

Fig. 6

Evodiamine exhibits anti-tumor activity by elevation of CD8+ T cells in vivo. a Evodiamine treatment does not change the body weight. b The survival rate of LLC and evodiamine improves the survival of the mice. c-e Tumor volume is checked at the beginning of the treatment period. Evodiamine-inhibited repressed tumor growth is forecast to estimate the tumor volumes (c) and tumor size (d and e). f-h. Lymphocytes cells of tumor preparations are analyzed using flow cytometry with TNFα and Granzyme B, FIN-γ, CD4 and CD8, antibodies. The results were presented in three independent experiments with the mean ± S.D. (n = 3, *P < 0.05; **P < 0.01; ***P < 0.001)

Back to article page